Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Renal Metastases from a Nasal Cavity Mixed Squamous Cell and Adenoid Cystic Carcinoma: A Case Report.

Longo R, Jaud C, Gehin W, Hennequin L, Bastien C, Campitiello M, Rozzi A, Plastino F.

Am J Case Rep. 2020 Jan 8;21:e919781. doi: 10.12659/AJCR.919781.

2.

A paraneoplastic limbic encephalitis from an anorectal small cell neuroendocrine carcinoma: a case report.

Longo R, Wagner M, Savenkoff B, de Castaing MC, Desiro G, Tubail Z, Hennequin L, Mahmoud SB, Marcon N, Quetin P, Campitiello M, Plastino F.

BMC Neurol. 2019 Nov 29;19(1):304. doi: 10.1186/s12883-019-1542-9.

3.

Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.

Ouvry G, Clary L, Tomas L, Aurelly M, Bonnary L, Borde E, Bouix-Peter C, Chantalat L, Defoin-Platel C, Deret S, Forissier M, Harris CS, Isabet T, Lamy L, Luzy AP, Pascau J, Soulet C, Taddei A, Taquet N, Thoreau E, Varvier E, Vial E, Hennequin LF.

ACS Med Chem Lett. 2019 Oct 4;10(11):1561-1567. doi: 10.1021/acsmedchemlett.9b00401. eCollection 2019 Nov 14.

PMID:
31749911
4.

A Subset of Type I Conventional Dendritic Cells Controls Cutaneous Bacterial Infections through VEGFα-Mediated Recruitment of Neutrophils.

Janela B, Patel AA, Lau MC, Goh CC, Msallam R, Kong WT, Fehlings M, Hubert S, Lum J, Simoni Y, Malleret B, Zolezzi F, Chen J, Poidinger M, Satpathy AT, Briseno C, Wohn C, Malissen B, Murphy KM, Maini AA, Vanhoutte L, Guilliams M, Vial E, Hennequin L, Newell E, Ng LG, Musette P, Yona S, Hacini-Rachinel F, Ginhoux F.

Immunity. 2019 Apr 16;50(4):1069-1083.e8. doi: 10.1016/j.immuni.2019.03.001. Epub 2019 Mar 27.

PMID:
30926233
5.

Application of the Tissue Composition-Based Model to Minipig for Predicting the Volume of Distribution at Steady State and Dermis-to-Plasma Partition Coefficients of Drugs Used in the Physiologically Based Pharmacokinetics Model in Dermatology.

Poulin P, Collet SH, Atrux-Tallau N, Linget JM, Hennequin L, Wilson CE.

J Pharm Sci. 2019 Jan;108(1):603-619. doi: 10.1016/j.xphs.2018.09.001. Epub 2018 Sep 14.

PMID:
30222978
6.

Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.

Fournier JF, Bhurruth-Alcor Y, Musicki B, Aubert J, Aurelly M, Bouix-Peter C, Bouquet K, Chantalat L, Delorme M, Drean B, Duvert G, Fleury-Bregeot N, Gauthier B, Grisendi K, Harris CS, Hennequin LF, Isabet T, Joly F, Lafitte G, Millois C, Morgentin R, Pascau J, Piwnica D, Rival Y, Soulet C, Thoreau É, Tomas L.

Bioorg Med Chem Lett. 2018 Sep 15;28(17):2985-2992. doi: 10.1016/j.bmcl.2018.06.029. Epub 2018 Jun 18.

PMID:
30122227
7.

Peritoneal Myeloid Sarcoma in a Patient Treated for a Testicular Seminoma.

Longo R, Dorvaux V, Chatelain E, Quétin P, Plastino F, Eid N, Marcon N, Hennequin L, Campitiello M.

Am J Case Rep. 2018 Jun 29;19:763-766. doi: 10.12659/AJCR.910434.

8.

Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.

Fournier JF, Clary L, Chambon S, Dumais L, Harris CS, Millois C, Pierre R, Talano S, Thoreau É, Aubert J, Aurelly M, Bouix-Peter C, Brethon A, Chantalat L, Christin O, Comino C, El-Bazbouz G, Ghilini AL, Isabet T, Lardy C, Luzy AP, Mathieu C, Mebrouk K, Orfila D, Pascau J, Reverse K, Roche D, Rodeschini V, Hennequin LF.

J Med Chem. 2018 May 10;61(9):4030-4051. doi: 10.1021/acs.jmedchem.8b00067. Epub 2018 Apr 24.

PMID:
29648825
9.

Sulfoximines as potent RORγ inverse agonists.

Ouvry G, Bihl F, Bouix-Peter C, Christin O, Defoin-Platel C, Deret S, Feret C, Froude D, Hacini-Rachinel F, Harris CS, Hervouet C, Lafitte G, Luzy AP, Musicki B, Orfila D, Parnet V, Pascau C, Pascau J, Pierre R, Raffin C, Rossio P, Spiesse D, Taquet N, Thoreau E, Vatinel R, Vial E, Hennequin LF.

Bioorg Med Chem Lett. 2018 May 1;28(8):1269-1273. doi: 10.1016/j.bmcl.2018.03.041. Epub 2018 Mar 17.

PMID:
29571573
10.

Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.

Ouvry G, Atrux-Tallau N, Bihl F, Bondu A, Bouix-Peter C, Carlavan I, Christin O, Cuadrado MJ, Defoin-Platel C, Deret S, Duvert D, Feret C, Forissier M, Fournier JF, Froude D, Hacini-Rachinel F, Harris CS, Hervouet C, Huguet H, Lafitte G, Luzy AP, Musicki B, Orfila D, Ozello B, Pascau C, Pascau J, Parnet V, Peluchon G, Pierre R, Piwnica D, Raffin C, Rossio P, Spiesse D, Taquet N, Thoreau E, Vatinel R, Vial E, Hennequin LF.

ChemMedChem. 2018 Feb 20;13(4):321-337. doi: 10.1002/cmdc.201700758. Epub 2018 Feb 6.

PMID:
29327456
11.

Breast metastasis from squamous cell carcinoma of the oropharynx: a case report.

Longo R, Melgar E, Campitiello M, Plastino F, Eid N, Quirin I, Hennequin L, Grignon Y, Gunther M, Quétin P.

J Med Case Rep. 2017 Dec 22;11(1):355. doi: 10.1186/s13256-017-1500-3.

12.

Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.

Boiteau JG, Ouvry G, Arlabosse JM, Astri S, Beillard A, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Cardinaud I, Comino C, Deprez B, Duvert D, Féret A, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Orsini N, Pascau J, Pinto A, Piwnica D, Polge G, Reitz A, Reversé K, Rodeville N, Rossio P, Spiesse D, Tabet S, Taquet N, Tomas L, Vial E, Hennequin LF.

Bioorg Med Chem. 2018 Feb 15;26(4):945-956. doi: 10.1016/j.bmc.2017.07.054. Epub 2017 Aug 2.

PMID:
28818461
13.

Identification of novel TACE inhibitors compatible with topical application.

Ouvry G, Berton Y, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Chambon S, Comino C, Deprez B, Duvert D, Duvert G, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Pascau J, Pinto A, Polge G, Reitz A, Reversé K, Rosignoli C, Taquet N, Hennequin LF.

Bioorg Med Chem Lett. 2017 Apr 15;27(8):1848-1853. doi: 10.1016/j.bmcl.2017.02.035. Epub 2017 Feb 20.

PMID:
28274635
14.

Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.

Wendel C, Campitiello M, Plastino F, Eid N, Hennequin L, Quétin P, Longo R.

Am J Case Rep. 2017 Jan 3;18:7-11.

15.

Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists.

Ouvry G, Bouix-Peter C, Ciesielski F, Chantalat L, Christin O, Comino C, Duvert D, Feret C, Harris CS, Lamy L, Luzy AP, Musicki B, Orfila D, Pascau J, Parnet V, Perrin A, Pierre R, Polge G, Raffin C, Rival Y, Taquet N, Thoreau E, Hennequin LF.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5802-5808. doi: 10.1016/j.bmcl.2016.10.023. Epub 2016 Oct 12.

PMID:
27815118
16.

Grey Turner's sign associated with hemorrhagic pancreatitis.

Gaci R, Cadoz C, Hennequin L, Louis G.

Intensive Care Med. 2017 Feb;43(2):265-266. doi: 10.1007/s00134-016-4551-9. Epub 2016 Sep 30. No abstract available.

PMID:
27695892
17.

Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.

Barlaam B, Cosulich S, Degorce S, Fitzek M, Giordanetto F, Green S, Inghardt T, Hennequin L, Hancox U, Lambert-van der Brempt C, Morgentin R, Pass S, Plé P, Saleh T, Ward L.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3928-35. doi: 10.1016/j.bmcl.2014.06.040. Epub 2014 Jun 21.

PMID:
24992874
18.

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C, Trigwell C, Vincent J, Ogilvie D.

ACS Med Chem Lett. 2013 May 31;4(8):742-6. doi: 10.1021/ml400146c. eCollection 2013 Aug 8.

19.

Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.

Plé PA, Jung F, Ashton S, Hennequin L, Laine R, Lambert-van der Brempt C, Morgentin R, Pasquet G, Taylor S.

Bioorg Med Chem Lett. 2012 May 1;22(9):3050-5. doi: 10.1016/j.bmcl.2012.03.074. Epub 2012 Mar 28.

PMID:
22497760
20.

Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.

Plé PA, Jung F, Ashton S, Hennequin L, Laine R, Morgentin R, Pasquet G, Taylor S.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6. doi: 10.1016/j.bmcl.2011.11.019. Epub 2011 Nov 12.

PMID:
22153662
21.

Efficient three-step one-pot synthesis of a novel 2,3,5-substituted pyrazine library.

Delvare C, Harris CS, Hennequin L, Koza P, Lambert-van der Brempt C, Pelleter J, Willerval O.

ACS Comb Sci. 2011 Sep 12;13(5):449-52. doi: 10.1021/co200062n. Epub 2011 Jul 1.

PMID:
21648463
22.

Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.

Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25.

23.

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.

Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Plé PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF.

Mol Oncol. 2009 Jun;3(3):248-61. doi: 10.1016/j.molonc.2009.01.002. Epub 2009 Feb 7.

24.

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

Ballard P, Barlaam BC, Bradbury RH, Dishington A, Hennequin LF, Hickinson DM, Hollingsworth IM, Kettle JG, Klinowska T, Ogilvie DJ, Pearson SE, Scott JS, Suleman A, Whittaker R, Williams EJ, Wood R, Wright L.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6326-9. Epub 2007 Sep 2.

PMID:
17869514
25.

Embolisation of symptomatic pelvic veins in women presenting with non-saphenous varicose veins of pelvic origin - three-year follow-up.

Creton D, Hennequin L, Kohler F, Allaert FA.

Eur J Vasc Endovasc Surg. 2007 Jul;34(1):112-7. Epub 2007 Mar 1.

26.

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.

Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Plé PA, Warin N, Costello G.

J Med Chem. 2006 Nov 2;49(22):6465-88.

PMID:
17064066
27.

Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Kettle JG, Kendrew J, Klinowska T, Ogilvie DJ, Pearson SE, Williams EJ, Wilson I.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4908-12. Epub 2006 Jun 27.

PMID:
16806916
28.

Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.

Hennequin LF, Ballard P, Boyle FT, Delouvrié B, Ellston RP, Halsall CT, Harris CS, Hudson K, Kendrew J, Pease JE, Ross HS, Smith P, Vincent JL.

Bioorg Med Chem Lett. 2006 May 15;16(10):2672-6. Epub 2006 Mar 3.

PMID:
16516473
29.

Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Johnson PD, Kettle JG, Klinowska T, Leach AG, Morgentin R, Pass M, Ogilvie DJ, Olivier A, Warin N, Williams EJ.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1633-7. Epub 2005 Dec 27.

PMID:
16380259
30.

New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors.

Barlaam B, Fennell M, Germain H, Green T, Hennequin L, Morgentin R, Olivier A, Plé P, Vautier M, Costello G.

Bioorg Med Chem Lett. 2005 Dec 15;15(24):5446-9. Epub 2005 Oct 3.

PMID:
16203139
31.

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.

Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Johnson PD, Kettle JG, Klinowska T, Morgentin R, Ogilvie DJ, Olivier A.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4226-9.

PMID:
16055332
32.

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ.

Cancer Res. 2005 May 15;65(10):4389-400.

33.

Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.

Plé PA, Green TP, Hennequin LF, Curwen J, Fennell M, Allen J, Lambert-Van Der Brempt C, Costello G.

J Med Chem. 2004 Feb 12;47(4):871-87.

PMID:
14761189
34.

ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity.

Whittles CE, Pocock TM, Wedge SR, Kendrew J, Hennequin LF, Harper SJ, Bates DO.

Microcirculation. 2002 Dec;9(6):513-22.

PMID:
12483548
35.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF.

Cancer Res. 2002 Aug 15;62(16):4645-55.

36.

Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling.

Gasmi A, Bourcier C, Aloui Z, Srairi N, Marchetti S, Gimond C, Wedge SR, Hennequin L, Pouysségur J.

J Biol Chem. 2002 Aug 16;277(33):29992-8. Epub 2002 May 20.

37.

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.

J Med Chem. 2002 Mar 14;45(6):1300-12.

PMID:
11881999
38.

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF.

Cancer Res. 2000 Feb 15;60(4):970-5.

39.

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C.

J Med Chem. 1999 Dec 30;42(26):5369-89.

PMID:
10639280
40.

Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.

Marsham PR, Wardleworth JM, Boyle FT, Hennequin LF, Kimbell R, Brown M, Jackman AL.

J Med Chem. 1999 Sep 23;42(19):3809-20.

PMID:
10508430
41.

[Prognostic factors of Pneumocystis carinii pneumonia in AIDS].

Hoen B, Viel JF, Maignan M, Hennequin L, May T, Amiel C, Kures L, Canton P.

Presse Med. 1996 Mar 16;25(9):443-8. French.

PMID:
8685193
42.

Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent.

Hennequin LF, Boyle FT, Wardleworth JM, Marsham PR, Kimbell R, Jackman AL.

J Med Chem. 1996 Feb 2;39(3):695-704.

PMID:
8576912
43.

Superior vena cava stent placement: results with the Wallstent endoprosthesis.

Hennequin LM, Fade O, Fays JG, Bic JF, Jaafar S, Bertal A, Anthoine D, Bernadac PA.

Radiology. 1995 Aug;196(2):353-61.

PMID:
7617844
44.

Thrombo-embolism during amniotic fluid embolism.

Bauer P, Lelarge P, Hennequin L, Lambert H, Larcan A.

Intensive Care Med. 1995 Apr;21(4):384. No abstract available.

PMID:
7650263
45.

Renal artery stent placement: long-term results with the Wallstent endoprosthesis.

Hennequin LM, Joffre FG, Rousseau HP, Aziza R, Tregant P, Bernadet P, Salvador M, Chamontin B.

Radiology. 1994 Jun;191(3):713-9.

PMID:
8184051
46.

[Techniques and complications of interventional radiology in vascular diseases of transplanted kidneys].

Fays J, Hennequin L.

J Radiol. 1994 Jan;75(1):77-80. Review. French.

PMID:
8151547
47.

[Pulmonary artery obstruction demonstrated by thoracic x-ray computed tomography].

Kheir A, Hennequin L, Hanifi M, Beysang R, Dollet JM.

Rev Mal Respir. 1994;11(1):77-8. French. No abstract available.

PMID:
8128102
48.

Synthesis and biological activity of C-3' ortho dihydroxyphthalimido cephalosporins.

Baudart MG, Hennequin LF.

J Antibiot (Tokyo). 1993 Sep;46(9):1458-70.

49.

[Absence of mitral valve prolapse during panic attacks induced by sodium lactate].

Moigne E, Pichene C, Hennequin L, Hoffman M, Lambert H, Larcan A.

Presse Med. 1993 May 22;22(18):850-4. Review. French.

PMID:
8337215
50.

[Viral pneumopathies after heart transplantation. Radioclinical analysis].

Chabot F, Hennequin L, Moreau L, Mattei MF, Villemot JP, Polu JM.

Presse Med. 1992 Dec 2;21(41):1999-2000. French.

PMID:
1338227

Supplemental Content

Loading ...
Support Center